Minor Cancer-Immunity-Personalized therapies (M_BCIPT19)
Summary
Samenvatting CIPT minor
0 purchase
Course
Minor Cancer-Immunity-Personalized therapies (M_BCIPT19)
Institution
Vrije Universiteit Amsterdam (VU)
issued every week of period 1 of the CIPT minor in Medicine. It contains all the information you need to get a good grade. the exam consists of open questions, but you will definitely pass it with this summary.
Own rating: 8.5
Minor Cancer-Immunity-Personalized therapies (M_BCIPT19)
All documents for this subject (10)
Seller
Follow
nooralkemade
Reviews received
Content preview
Week 1: Neuroimmunolgy
Clinical aspects of MS
Epidemiology:
● More women than men → 2-3:1
● Typical age: 20-40 years. Age at onset is often lower in females.
● A western disease: Further from the equator → less UV light → lower serum Vitamin
D → higher risk of MS. Not yet been proved, but there seems to be an association.
Pathology:
● MS is exclusively in the CNS. A complex interaction between the immune system,
neurons and glia result in inflammation and destruction of the CNS.
● Major pathological process: Demyelination = breakdown myelin + destruction
oligodendrocytes. B and T cell response → inflammatory process which can be
targeted by therapy.
● Demyelinating lesions: located in the periventricular and juxtacortical regions and
spinal cord (brain stem, cerebellum, optic nerve)
● Degeneration: neuronal loss of chronically demyelinated axons, gliosis of astrocytes
and activated microglia.
Cause: MS is familial: increased risk within the family. HLA region in chromosome 6 has
been associated with MS. Over 200 allelic variants in genes have been identified as a risk
factor for MS.
Symptoms:
Most MS patients have symptoms arising from one or more places of inflammation. The
symptoms typically increase in a relapse, and then complete or incompletely stay for some
time.
● Optic neuritis: decreased vision, mainly in the central visual fields. Disturbance of
colour vision. And pain behind the eye. (This manifestation can also be with other
auto-immune diseases. patients presenting this have a 25-72% chance of MS).
● Eye movement: abnormal. most common is double vision and involuntary eye
movement.
● Lhermitte’s symptom: flexion of the neck causes an electrical-like shooting sensation.
● Motor function: weakness of the limbs. Mostly at one side of the brain, and often arm
& leg.
● Bladder function: due to the lower nerves.
● Psychological functions: slowing of processing, attention deficit, disturbance of
memory and language processing.
● Fatigue: most common and high impact. The cause is unknown.
Diagnosis:
Relapsing-remitting MS (RRMS): occurs at the onset. Symptoms come and go. Tissue
damage accumulates and then they move to the secondary progressive phase.
Secondary progressive MS (SPMS): initial relapse remitting and then suddenly begins to
decline without a period of remission.
, Picture:
First RRMS with ups and downs → then
reaching threshold → become SPSM with minimal
ups and downs → then improvements are only
worsening.
The first stage has more inflammation, the second stage is more degeneration
Diagnosing using the McDonald criteria of 2017. Dysfunction of a variable brain or spinal cord
areas on more than one occasion in time.
> Dissemination in space: two of the four places where the lesions can happen. Someone
with optic neuritis only cannot be labelled as an MS patient.
> Dissemination in time: >1 relapse. MRI shows new lesions. Use contrast to see new
versus old lesions. The presence of oligoclonal bands can be seen in the cerebrospinal fluid.
CSF: used in the diagnosis of MS.
● Oligoclonal bands: antibodies. are always present independent of the relapsing
phase. high sensitivity (90%), and lower specificity.
● IgG index: ration CSF and IgG in serum. Not often used because this could indicate
all types of auto-immune diseases.
Treatment:
● The window of opportunity: active white matter demyelination in the relapsing phase.
● First-line therapy: less effective but also has fewer side effects.
● Second-line therapy: more aggressive treatment.
● Early therapy is needed to delay the accumulation of irreversible neurological
damage.
● Effectiveness vs. risks: Natalizumab is very effective, but the chance of opportunistic
viral infection is bigger → possibility of severe disability or death
Histopathology of MS/Practical class of MS pathology
Main aspects revolving around MS:
● Long clinical course → >40 years
● Hallmarks of MS: demyelination, inflammation/immune response and involvement of
both WM and GM.
● Outside-in hypothesis: a primary autoimmune attack causes myelin and axonal
degeneration in the CNS.
● Inside-out hypothesis: a primary cyto-degenerative process causes myelin
degeneration in the CNS and a secondary autoimmune attack against the
fragmented myelin.
● Spotting the basic hallmarks: myelin proteins in the membrane. PLP is often used.
No PLP = lesion. (PLP colours brown).
White matter lesions: classify based on the level of inflammation. Use APC markers like
MHC-II.
● Active: high MHC-II reactivity inside the lesion. A lot of macrophages and active
microglia. This indicates a new lesion.
● Chronic active: high MHC-II reactivity at the rim. Fewer macrophages. Older lesion
than active.
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller nooralkemade. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $8.58. You're not tied to anything after your purchase.
